Ergoteles’s Aldeyra Therapeutics ALDX Stock Holding History

Ergoteles’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-238,500	Closed	-$952K	–	1512
2022 Q2	$952K	Buy	+238,500	New	+$820K	0.03%	562
2022 Q1	–	Sell	-114,795	Closed	-$459K	–	1182
2021 Q4	$459K	Buy	+114,795	New	+$876K	0.02%	676
2021 Q1	–	Sell	-34,985	Closed	-$240K	–	778
2020 Q4	$240K	Buy	+34,985	New	+$246K	0.01%	567

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Ergoteles's ALDX Position: Q3 2022 in Review

Ergoteles sold out of Aldeyra Therapeutics (ALDX) in Q3 2022, closing a stake of 238,500 shares — an estimated $952K sold.

Ergoteles first reported a position in ALDX in Q4 2020 and held it in 3 quarters. The position peaked at $952K in Q2 2022. 89 funds tracked by Wall St. Rank hold ALDX as of Q3 2022.

Ergoteles reported no remaining Aldeyra Therapeutics position as of Q3 2022 after selling out during the quarter.
Ergoteles sold 238,500 Aldeyra Therapeutics shares in Q3 2022, an estimated $952K.
Ergoteles first reported a position in Aldeyra Therapeutics in Q4 2020 and held it in 3 quarters.
Ergoteles's Aldeyra Therapeutics position peaked at $952K in Q2 2022.
89 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.